Total income of the company rose to Rs 2,428 crore for the third quarter
Cadila Healthcare has posted 38 per cent rise in consolidated net profit at Rs 390 crore for the third quarter ended December 31, on the back of robust sales in the US market. The company had posted a net profit of Rs 282 in the same period of previous fiscal.
Total income of the company rose to Rs 2,428 crore for the third quarter compared with Rs 2,205 crore in the corresponding quarter of the previous year on a consolidated basis, Cadila Healthcare said in a statement.
During the quarter, the company’s business in the US posted sales of Rs 1,072 crore registering a growth of 20 per cent over the same period of previous year. The company filed 20 abbreviated new drug applications (ANDAs) with the US FDA during the quarter.
The company said it launched 12 new products, including line extensions, in the domestic market. In Brazil, the company received the regulatory approval for two products during the quarter.